On 25 July 2019, orphan designation EU/3/19/2184 was granted by the European Commission to Voisin Consulting S.A.R.L., France, for N-((R)-2,3-dihydroxypropoxyl)-3,4-difluro-2-(2-fluoro-4-iodo-phenylamino)-benzamide (also known as PD-0325901) for the treatment of neurofibromatosis type 1.
|Disease / condition||
Treatment of neurofibromatosis type 1
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.